AI Medical Devices — FDA Clearance Transparency and Post-Market Surveillance Gaps
OVERVIEWOverview STAT News investigation into "AI medical devices' dirty FDA secret" reveals significant transparency gaps in how AI device performance data is disclosed to clinicians, patients, and the public. Devices may receive FDA clearance based on validation studies conducted under conditions that differ substantially from real-world clinical deployment, with limited mechanisms for post-market performance monitoring. Transparency Gaps FDA clearance documentation for AI medical devices often lacks sufficient detail about validation study populations, performance across demographic subgroups, and the conditions under which performance claims were established. Clinicians making deployment decisions may lack the information needed to assess whether a cleared device will perform as expected in their patient population. Post-Market Surveillance Limitations Current FDA post-market surveillance requirements for AI medical devices are less robust than for high-risk implantable devices, creating a situation where performance problems may not be systematically detected or reported. Adverse events associated with AI device errors may be attributed to other causes, further obscuring the true performance record. Reform Priorities Addressing these gaps requires enhanced pre-market disclosure requirements, mandatory post-market performance reporting, public databases of AI device performance data, and mechanisms for clinicians to report AI device performance concerns analogous to MedWatch for…
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.